Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
Behr
Thomas M
TM
Béhé
Martin
M
Kluge
Gerald
G
Gotthardt
Martin
M
Schipper
Meike L
ML
Gratz
Stefan
S
Arnold
Rudolf
R
Becker
Wolfgang
W
Goldenberg
David M
DM
D000818:Animals; D006801:Humans; D007668:Kidney / Q000293:injuries / Q000528:radiation effects*; D009369:Neoplasms / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
D010455:Peptides; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide